We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Read MoreHide Full Article
Key Takeaways
Merit Medical raised its 2026 revenue and adjusted earnings outlook after stronger first-half results.
Therapeutic products are projected to grow 9.1% from 2025-2028, versus 4.7% for Foundational products.
Merit Medical trades at 20.3X forward earnings versus 17.6X for its sub-industry, raising execution pressure.
Merit Medical Systems, Inc. (MMSI - Free Report) is showing a better operating trajectory as therapeutic products, recent launches and acquisitions broaden its growth mix. Earnings expectations have also improved, strengthening the fundamental case.
The trade-off is valuation. MMSI still carries a premium to its Zacks sub-industry, leaving less room for execution misses even as its growth outlook becomes more favorable.
Merit Medical’s Growth Case Is Getting Stronger
For 2026, the Zacks model projects revenues and adjusted earnings per share to increase 7.6% and 11.5%, respectively. The company also raised its 2026 revenue and adjusted earnings outlook after stronger-than-expected first-half results.
From 2025 through 2028, revenues and adjusted earnings are projected to post compound annual growth rates of 6.2% and 8.9%, respectively. Therapeutic products are expected to grow at a 9.1% rate, ahead of 4.7% for Foundational products, improving the mix toward faster-growing categories.
Image Source: Zacks Investment Research
MMSI’s Valuation Leaves Less Room for Error
MMSI trades at 20.3X forward 12-month earnings compared with 17.6X for its Zacks sub-industry. That premium means further upside depends more heavily on sustained revenue growth, margin execution and continued earnings delivery.
The multiple is below MMSI's five-year median of 24.5X, which tempers the valuation concern. Still, the stock is not inexpensive relative to its sub-industry, so stronger fundamentals need to translate into consistent results.
Image Source: Zacks Investment Research
New MMSI Platforms Add Longer-Term Optionality
The View Point Medical acquisition added the OneMark Detection Imaging System and OneMark Tissue Markers to Merit Medical's oncology portfolio. Combined with the late-May launch of SCOUT MD, the technologies broaden breast-care localization options across diagnosis and surgery.
Endoscopy also gained the Resilience Through-the-Scope Esophageal Stent and C2 CryoBalloon. WRAPSODY remains a multi-year renal-therapy opportunity, although the unchanged $7 million U.S. revenue assumption for 2026 keeps near-term expectations measured.
Image Source: Zacks Investment Research
Merit Medical Faces Tariff and Execution Risks
Management now expects a 2026 tariff burden of approximately $16 million, or 21 cents per share, up from its prior assumption. Buyer consolidation, distributor dependence in some international markets and currency volatility can also pressure pricing and visibility.
Competition remains broad. Boston Scientific Corporation (BSX - Free Report) operates across endoscopy and cardiovascular devices, creating overlap with several Merit Medical procedure areas. Medtronic plc (MDT - Free Report) also reports Cardiovascular and Surgical & Endoscopy businesses, underscoring the need for Merit Medical to support launches while defending established positions.
Merit Medical ended the second quarter with $448.7 million in cash and cash equivalents and $736.3 million in long-term debt. Its debt-to-capital ratio was 30.5%, below the industry level of 50.5%.
Management is building an M&A playbook and broader capital-allocation framework as part of its 2027-2029 strategic planning process. That liquidity can support potential tuck-in acquisitions and product-pipeline priorities, although deployment discipline remains important.
MMSI Signals Support a Patient Stance
MMSI's improving growth mix, portfolio expansion and stronger earnings outlook support the fundamental case, but the valuation premium and execution risks argue against treating the setup as an easy decision. The balance remains constructive rather than decisive.
The stock currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A and VGM Score of B are favorable, while its Value Score of C and Growth Score of C are more middle-of-the-pack. Taken together, the signals support patience while investors watch whether execution can justify the premium. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Key Takeaways
Merit Medical Systems, Inc. (MMSI - Free Report) is showing a better operating trajectory as therapeutic products, recent launches and acquisitions broaden its growth mix. Earnings expectations have also improved, strengthening the fundamental case.
The trade-off is valuation. MMSI still carries a premium to its Zacks sub-industry, leaving less room for execution misses even as its growth outlook becomes more favorable.
Merit Medical’s Growth Case Is Getting Stronger
For 2026, the Zacks model projects revenues and adjusted earnings per share to increase 7.6% and 11.5%, respectively. The company also raised its 2026 revenue and adjusted earnings outlook after stronger-than-expected first-half results.
From 2025 through 2028, revenues and adjusted earnings are projected to post compound annual growth rates of 6.2% and 8.9%, respectively. Therapeutic products are expected to grow at a 9.1% rate, ahead of 4.7% for Foundational products, improving the mix toward faster-growing categories.
Image Source: Zacks Investment Research
MMSI’s Valuation Leaves Less Room for Error
MMSI trades at 20.3X forward 12-month earnings compared with 17.6X for its Zacks sub-industry. That premium means further upside depends more heavily on sustained revenue growth, margin execution and continued earnings delivery.
The multiple is below MMSI's five-year median of 24.5X, which tempers the valuation concern. Still, the stock is not inexpensive relative to its sub-industry, so stronger fundamentals need to translate into consistent results.
Image Source: Zacks Investment Research
New MMSI Platforms Add Longer-Term Optionality
The View Point Medical acquisition added the OneMark Detection Imaging System and OneMark Tissue Markers to Merit Medical's oncology portfolio. Combined with the late-May launch of SCOUT MD, the technologies broaden breast-care localization options across diagnosis and surgery.
Endoscopy also gained the Resilience Through-the-Scope Esophageal Stent and C2 CryoBalloon. WRAPSODY remains a multi-year renal-therapy opportunity, although the unchanged $7 million U.S. revenue assumption for 2026 keeps near-term expectations measured.
Image Source: Zacks Investment Research
Merit Medical Faces Tariff and Execution Risks
Management now expects a 2026 tariff burden of approximately $16 million, or 21 cents per share, up from its prior assumption. Buyer consolidation, distributor dependence in some international markets and currency volatility can also pressure pricing and visibility.
Competition remains broad. Boston Scientific Corporation (BSX - Free Report) operates across endoscopy and cardiovascular devices, creating overlap with several Merit Medical procedure areas. Medtronic plc (MDT - Free Report) also reports Cardiovascular and Surgical & Endoscopy businesses, underscoring the need for Merit Medical to support launches while defending established positions.
MMSI’s Balance Sheet Supports Strategic Flexibility
Merit Medical ended the second quarter with $448.7 million in cash and cash equivalents and $736.3 million in long-term debt. Its debt-to-capital ratio was 30.5%, below the industry level of 50.5%.
Management is building an M&A playbook and broader capital-allocation framework as part of its 2027-2029 strategic planning process. That liquidity can support potential tuck-in acquisitions and product-pipeline priorities, although deployment discipline remains important.
MMSI Signals Support a Patient Stance
MMSI's improving growth mix, portfolio expansion and stronger earnings outlook support the fundamental case, but the valuation premium and execution risks argue against treating the setup as an easy decision. The balance remains constructive rather than decisive.
The stock currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A and VGM Score of B are favorable, while its Value Score of C and Growth Score of C are more middle-of-the-pack. Taken together, the signals support patience while investors watch whether execution can justify the premium. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.